Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023) -- By Region (North America, Europe, APAC), By Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China)
Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global biopharmaceutical Contract Manufacturing Organisation (CMO) market. The report titled “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)” analyses the global market as well as the market by Region (North America, Europe and Asia Pacific) and by Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China.
According to Azoth Analytics research report “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)”, the global market value is projected to display a steady growth represented by a CAGR of 14.36% during the forecast period of 2018 – 2023.
Amongst the regions, Europe accounts for the largest share by value in global Bio CMO market in 2017. Additionally, Asia Pacific will be a growing region in the forecasted period, 2018-2023 as population is increasing along with growing number of pharmaceutical requirements. Growing number of chronic diseases is also supporting the market of Bio CMO industry.
The report titled “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)” has covered and analyzed the potential of Global Bio CMO Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global Bio CMO market. Additionally, the report also assesses the financial performance and strategies of various companies operating in the Biopharmaceutical CMO market.
Scope of the Report
Global Bio CMO Market (Actual Period: 2013-2017, Forecast Period: 2018-2023
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global biopharmaceutical Contract Manufacturing Organisation (CMO) market. The report titled “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)” analyses the global market as well as the market by Region (North America, Europe and Asia Pacific) and by Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China.
According to Azoth Analytics research report “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)”, the global market value is projected to display a steady growth represented by a CAGR of 14.36% during the forecast period of 2018 – 2023.
Amongst the regions, Europe accounts for the largest share by value in global Bio CMO market in 2017. Additionally, Asia Pacific will be a growing region in the forecasted period, 2018-2023 as population is increasing along with growing number of pharmaceutical requirements. Growing number of chronic diseases is also supporting the market of Bio CMO industry.
The report titled “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)” has covered and analyzed the potential of Global Bio CMO Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global Bio CMO market. Additionally, the report also assesses the financial performance and strategies of various companies operating in the Biopharmaceutical CMO market.
Scope of the Report
Global Bio CMO Market (Actual Period: 2013-2017, Forecast Period: 2018-2023
- Global Bio CMO Market – By value
- By Type – Mammalian & Microbial
- Bio CMO Market – By value
- Bio CMO Market – By value
- Market Dynamics – Drivers and Restraints
- Company Analysis – Lonza, Boehringer Ingelheium, Samsung Biologics, Wuxi Biologics
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. BIOPHARMACEUTICAL CMO MARKET OUTLOOK
4. GLOBAL BIO CMO MARKET : GROWTH AND FORECAST
4.1 Global Bio CMO Market, By Value (2013-2017) (USD Billion)
4.2 Global Bio CMO Market, By Value (2018-2023) (USD Billion)
5. GLOBAL BIOPHARMACEUTICAL MARKET: SEGMENT ANALYSIS
6. NORTH AMERICA BIO CMO MARKET: GROWTH AND FORECAST
6.1 North America Market, By Value (2013-2017)(USD Billion)
6.2 North America Market, By Value (2018-2023)(USD Billion)
7. U.S BIO CMO MARKET, BY INDICATIONS
8. CANADA BIO CMO MARKET , BY INDICATIONS
9. EUROPE BIO CMO MARKET: GROWTH AND FORECAST
9.1 Europe Market, By Value (2013-2017)(USD Billion)
9.2 Europe Market, By Value (2018-2023)(USD Billion)
10. GERMANY BIO CMO MARKET, BY INDICATIONS
11. U.K BIO CMO MARKET, BY INDICATIONS
12. FRANCE BIO CMO MARKET, BY INDICATIONS
13. APAC BIO CMO MARKET : GROWTH AND FORECAST
13.1 APAC Market, By Value (2013-2017)(USD Billion)
13.2 APAC Market, By Value (2018-2023)(USD Billion)
14. CHINA BIO CMO MARKET, BY INDICATIONS
15. INDIA BIO CMO MARKET, BY INDICATIONS
16. JAPAN BIO CMO MARKET, BY INDICATIONS
17. BIO CMO MARKET: COUNTRY ANALYSIS
17.1 U.S Bio CMO Market, By Value (2013-2023) (USD Billion)
17.2 Denmark Bio CMO Market, By Value (2013-2023) (USD Billion)
17.3 Germany Bio CMO Market, By Value (2013-2023) (USD Billion)
17.4 Switzerland Bio CMO Market, By Value (2013-2023) (USD Billion)
17.5 Korea Bio CMO Market, By Value (2013-2023) (USD Billion)
17.6 Japan Bio CMO Market, By Value (2013-2023) (USD Billion)
17.7 China Bio CMO Market, By Value (2013-2023) (USD Billion)
17.8 Others Bio CMO Market, By Value (2013-2023) (USD Billion)
18. GLOBAL BIO CMO MARKET DYNAMICS
18.1 Global Bio CMO Market Drivers
18.2 Global Bio CMO Market Challenges
19. COMPANY PROFILES
19.1 Lonza
19.2 Boehringer Ingelheium
19.3 Samsung Biologics
19.4 Wuxi Biologics
2. EXECUTIVE SUMMARY
3. BIOPHARMACEUTICAL CMO MARKET OUTLOOK
4. GLOBAL BIO CMO MARKET : GROWTH AND FORECAST
4.1 Global Bio CMO Market, By Value (2013-2017) (USD Billion)
4.2 Global Bio CMO Market, By Value (2018-2023) (USD Billion)
5. GLOBAL BIOPHARMACEUTICAL MARKET: SEGMENT ANALYSIS
6. NORTH AMERICA BIO CMO MARKET: GROWTH AND FORECAST
6.1 North America Market, By Value (2013-2017)(USD Billion)
6.2 North America Market, By Value (2018-2023)(USD Billion)
7. U.S BIO CMO MARKET, BY INDICATIONS
8. CANADA BIO CMO MARKET , BY INDICATIONS
9. EUROPE BIO CMO MARKET: GROWTH AND FORECAST
9.1 Europe Market, By Value (2013-2017)(USD Billion)
9.2 Europe Market, By Value (2018-2023)(USD Billion)
10. GERMANY BIO CMO MARKET, BY INDICATIONS
11. U.K BIO CMO MARKET, BY INDICATIONS
12. FRANCE BIO CMO MARKET, BY INDICATIONS
13. APAC BIO CMO MARKET : GROWTH AND FORECAST
13.1 APAC Market, By Value (2013-2017)(USD Billion)
13.2 APAC Market, By Value (2018-2023)(USD Billion)
14. CHINA BIO CMO MARKET, BY INDICATIONS
15. INDIA BIO CMO MARKET, BY INDICATIONS
16. JAPAN BIO CMO MARKET, BY INDICATIONS
17. BIO CMO MARKET: COUNTRY ANALYSIS
17.1 U.S Bio CMO Market, By Value (2013-2023) (USD Billion)
17.2 Denmark Bio CMO Market, By Value (2013-2023) (USD Billion)
17.3 Germany Bio CMO Market, By Value (2013-2023) (USD Billion)
17.4 Switzerland Bio CMO Market, By Value (2013-2023) (USD Billion)
17.5 Korea Bio CMO Market, By Value (2013-2023) (USD Billion)
17.6 Japan Bio CMO Market, By Value (2013-2023) (USD Billion)
17.7 China Bio CMO Market, By Value (2013-2023) (USD Billion)
17.8 Others Bio CMO Market, By Value (2013-2023) (USD Billion)
18. GLOBAL BIO CMO MARKET DYNAMICS
18.1 Global Bio CMO Market Drivers
18.2 Global Bio CMO Market Challenges
19. COMPANY PROFILES
19.1 Lonza
19.2 Boehringer Ingelheium
19.3 Samsung Biologics
19.4 Wuxi Biologics
LIST OF FIGURES
Figure 1: Global In House Manufacturing By Value, 2013-2017 (USD Billion)
Figure 2: Global In House Manufacturing By Value, 2013-2017 (USD Billion)
Figure 3: Global Bio CMO Market Size, By Value, 2013-2017 (USD Billion)
Figure 4: Global Biologics market Outlook, 2012-2016 (In Billion )
Figure 5: Global Biologics market Outlook, 2012-2016 (In Billion)
Figure 6: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 7: Number of people with diabetes worldwide and per region in 2017 and 2045, (20-79 years)
Figure 8: Diabetes Prevalence, By Country, in % of population ages 20 to 79 in 2017
Figure 9: Global Bio CMO Market Size, By Value, 2018-2023 (USD Billion)
Figure 10: Global Bio CMO Market Size, By Segment, 2017 (%)
Figure 11: Global Bio CMO Market Size, By Segment, 2023 (%)
Figure 12: North America Bio CMO Size, By Value, 2013-2017 (USD Billion)
Figure 13: North America Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Figure 14: North America GDP, 2013-2017 (USD Trillion)
Figure 15: North America GDP, By Select Country, 2016 (USD Trillion)
Figure 16: North America Healthcare Cost Per Capita, By Select Country, 2016 (USD)
Figure 17: Number of Citizen 65 years and above, USA and Canada in Million 2016
Figure 18: Number of Citizen 65 years and above, USA and Canada in Million 2060
Figure 19: North America Prevalence of Gynecological Disorders (2012-2016)
Figure 20: Total Number of People with North America Neglected Tropical Disorders (2012-2016)
Figure 21: Total Number of People in North America with Different Type of Cardiovascular Disease in 2016
Figure 22: North America DALYs of Ischemic Heart Disease(2013-2016 %)
Figure 23: North America DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 24: North America DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 25: North America DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 26: North America DALYs of Diabetes Mellitus(2013-2016 %)
Figure 27: United States Prevalence of Diabetes (Per 1,00,000 )2013-2016
Figure 28: United States Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 29: Prevalence of Neurological Disorders in United States (2016, Million)
Figure 30: United States Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 31: United States DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 32: United States DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 33: United States DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 34: United States DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 35: United States DALYs of Diabetes Mellitus (2013-2016 %)
Figure 36: Canada Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Figure 37: Canada Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 38: Canada Total Number of People With Sense Organ Disorders (2012-2016)
Figure 39: Canada Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 40: Canada DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 41: Canada DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 42: Canada DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 43: Canada DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 44: Canada DALYs of Diabetes Mellitus (2013-2016 %)
Figure 45: Europe Bio CMO Size, By Value, 2013-2017 (USD Billion)
Figure 46: Europe Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Figure 47: Number Deaths due to cancer in Europe 2016
Figure 48: Share of older population 65 years and above as percentage of total population
Figure 49: Western Europe Prevalence of Gynecological (2012-2016, Million)
Figure 50: Western Europe Prevalence of Musculoskeletal Disorders (2012-2016, Million)
Figure 51: Total Number of People With Cardiovascular Disorders in Western Europe, By Type,2016
Figure 52: Western Europe DALYs of Ischemic Heart Disease (2013-2016), in %
Figure 53: Western Europe DALYs of Chronic Kidney Disease(2013-2016)in %
Figure 54: Western Europe DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 55: Western Europe DALYs of Alzheimer Disease and Other Dementias (2013-2016 )in %
Figure 56: Western Europe DALYs of Diabetes Mellitus (2013-2016 )in %
Figure 57: Germany Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 58: Total Number of People With Infectious Disorder in Germany (2012-2016)
Figure 59: Germany Prevalence of Neurological Disorders (2012-2016, Million)
Figure 60: Germany Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 61: Germany DALYs of Ischemic Heart Disease (2013-2016), in %
Figure 62: Germany DALYs of Chronic Kidney Disease (2013-2016), in %
Figure 63: Germany DALYs of Chronic Obstructive Pulmonary Disease(2013-2016), in%
Figure 64: Germany DALYs of Alzheimer Disease and Other Dementias (2013-2016), %
Figure 65: Germany DALYs of Diabetes Mellitus (2013-2016), %
Figure 66: United Kingdom DALYs of Ischemic Heart Disease (2013-2016), %
Figure 67: United Kingdom DALYs of Chronic Kidney Disease(2013-2016), %
Figure 68: United Kingdom DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 69: United Kingdom DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 70: United Kingdom DALYs of Diabetes Mellitus (2013-2016 %)
Figure 71: United Kingdom Prevalence of Cardiovascular Disorders (Per 1,00,000), 2013-2016
Figure 72: United Kingdom Prevalence of Diabetes Mellitus (Per 1,00,000), 2013-2016
Figure 73: United Kingdom Prevalence of Musculoskeletal Disorders (Per 1,00,000), 2013-2016
Figure 74: France DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 75: France DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 76: France DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 77: France DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 78: France DALYs of Diabetes Mellitus (2013-2016 %)
Figure 79: APAC Bio CMO Size, By Value, 2013-2017 (USD Billion)
Figure 80: APAC Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Figure 81: South East Asia, East Asia, Oceania , DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 82: South East Asia, East Asia, Oceania DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 83: South East Asia, East Asia, Oceania DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 84: South East Asia, East Asia, Oceania DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 85: South East Asia, East Asia, Oceania DALYs of Diabetes Mellitus (2013-2016 %)
Figure 86: China DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 87: China DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 88: China DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 89: China DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 90: China DALYs of Diabetes Mellitus (2013-2016 %)
Figure 91: China Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Figure 92: China Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 93: China Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 94: India Prevalence of Diabetes Mellitus (Per 1,00,000)2013-2016
Figure 95: India Prevalence of Musculoskeletal Disorders (Per 1,00,000) 2013-2016
Figure 96: India Prevalence of Cardiovascular Disorders (Per 1,00,000) 2013-2016
Figure 97: Total Number of People With Infectious Disorder in India (2012-2016)
Figure 98: India DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 99: India DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 100: India DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 101: India DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 102: India DALYs of Diabetes Mellitus (2013-2016 %)
Figure 103: Japan DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 104: Japan DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 105: Japan DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 106: Japan DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 107: Japan DALYs of Diabetes Mellitus(2013-2016 %)
Figure 108: Japan Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Figure 109: Japan Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 110: Japan Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 111: US Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 112: US Pharmaceutical Spending 2013-2017 in USD Billion
Figure 113: Revenue of companies engaged in speciality pharmacy in US 2016 (in million USD)
Figure 114: Denmark Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 115: Germany Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 116: Revenue of Germany Pharmaceutical Industry 2012-2016 in Billion USD
Figure 117: Switzerland Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 118: Swiss pharmaceutical industry export 2000
Figure 119: Swiss pharmaceutical industry export 2016
Figure 120: Korea Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 121: Japan Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 122: China Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 123: China Expenditure on Health and Medical Care 2012-2018 (in USD Billion)
Figure 124: Other’s Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 125: Lonza, Net Sales, 2014-2017 (In Billion USD)
Figure 126: Boehringer Ingelheim, Net Sales, 2013-2016 (In Million USD)
Figure 127: Boehringer Ingelheim Sales by Region, 2016
Figure 128: Boehringer Ingelheim Sales by Segment, 2016
Figure 129: Samsung Biologics, Net Sales, 2014-2017 (In Million USD)
Figure 130: Samsung Biologics, Biomedicine manufacturing plants, 2017
Figure 131: Wuxi Biologics, Net Sales, 2013-2016 (In Million USD)
Figure 132: Wuxi Biologics, Sales by Region, 2016
Figure 133: Boehringer Ingelheim Sales by Segment, 2016
Table 1: Japan Biopharmaceutical Market (100 million USD)
Figure 1: Global In House Manufacturing By Value, 2013-2017 (USD Billion)
Figure 2: Global In House Manufacturing By Value, 2013-2017 (USD Billion)
Figure 3: Global Bio CMO Market Size, By Value, 2013-2017 (USD Billion)
Figure 4: Global Biologics market Outlook, 2012-2016 (In Billion )
Figure 5: Global Biologics market Outlook, 2012-2016 (In Billion)
Figure 6: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 7: Number of people with diabetes worldwide and per region in 2017 and 2045, (20-79 years)
Figure 8: Diabetes Prevalence, By Country, in % of population ages 20 to 79 in 2017
Figure 9: Global Bio CMO Market Size, By Value, 2018-2023 (USD Billion)
Figure 10: Global Bio CMO Market Size, By Segment, 2017 (%)
Figure 11: Global Bio CMO Market Size, By Segment, 2023 (%)
Figure 12: North America Bio CMO Size, By Value, 2013-2017 (USD Billion)
Figure 13: North America Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Figure 14: North America GDP, 2013-2017 (USD Trillion)
Figure 15: North America GDP, By Select Country, 2016 (USD Trillion)
Figure 16: North America Healthcare Cost Per Capita, By Select Country, 2016 (USD)
Figure 17: Number of Citizen 65 years and above, USA and Canada in Million 2016
Figure 18: Number of Citizen 65 years and above, USA and Canada in Million 2060
Figure 19: North America Prevalence of Gynecological Disorders (2012-2016)
Figure 20: Total Number of People with North America Neglected Tropical Disorders (2012-2016)
Figure 21: Total Number of People in North America with Different Type of Cardiovascular Disease in 2016
Figure 22: North America DALYs of Ischemic Heart Disease(2013-2016 %)
Figure 23: North America DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 24: North America DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 25: North America DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 26: North America DALYs of Diabetes Mellitus(2013-2016 %)
Figure 27: United States Prevalence of Diabetes (Per 1,00,000 )2013-2016
Figure 28: United States Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 29: Prevalence of Neurological Disorders in United States (2016, Million)
Figure 30: United States Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 31: United States DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 32: United States DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 33: United States DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 34: United States DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 35: United States DALYs of Diabetes Mellitus (2013-2016 %)
Figure 36: Canada Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Figure 37: Canada Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 38: Canada Total Number of People With Sense Organ Disorders (2012-2016)
Figure 39: Canada Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 40: Canada DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 41: Canada DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 42: Canada DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 43: Canada DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 44: Canada DALYs of Diabetes Mellitus (2013-2016 %)
Figure 45: Europe Bio CMO Size, By Value, 2013-2017 (USD Billion)
Figure 46: Europe Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Figure 47: Number Deaths due to cancer in Europe 2016
Figure 48: Share of older population 65 years and above as percentage of total population
Figure 49: Western Europe Prevalence of Gynecological (2012-2016, Million)
Figure 50: Western Europe Prevalence of Musculoskeletal Disorders (2012-2016, Million)
Figure 51: Total Number of People With Cardiovascular Disorders in Western Europe, By Type,2016
Figure 52: Western Europe DALYs of Ischemic Heart Disease (2013-2016), in %
Figure 53: Western Europe DALYs of Chronic Kidney Disease(2013-2016)in %
Figure 54: Western Europe DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 55: Western Europe DALYs of Alzheimer Disease and Other Dementias (2013-2016 )in %
Figure 56: Western Europe DALYs of Diabetes Mellitus (2013-2016 )in %
Figure 57: Germany Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 58: Total Number of People With Infectious Disorder in Germany (2012-2016)
Figure 59: Germany Prevalence of Neurological Disorders (2012-2016, Million)
Figure 60: Germany Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 61: Germany DALYs of Ischemic Heart Disease (2013-2016), in %
Figure 62: Germany DALYs of Chronic Kidney Disease (2013-2016), in %
Figure 63: Germany DALYs of Chronic Obstructive Pulmonary Disease(2013-2016), in%
Figure 64: Germany DALYs of Alzheimer Disease and Other Dementias (2013-2016), %
Figure 65: Germany DALYs of Diabetes Mellitus (2013-2016), %
Figure 66: United Kingdom DALYs of Ischemic Heart Disease (2013-2016), %
Figure 67: United Kingdom DALYs of Chronic Kidney Disease(2013-2016), %
Figure 68: United Kingdom DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 69: United Kingdom DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 70: United Kingdom DALYs of Diabetes Mellitus (2013-2016 %)
Figure 71: United Kingdom Prevalence of Cardiovascular Disorders (Per 1,00,000), 2013-2016
Figure 72: United Kingdom Prevalence of Diabetes Mellitus (Per 1,00,000), 2013-2016
Figure 73: United Kingdom Prevalence of Musculoskeletal Disorders (Per 1,00,000), 2013-2016
Figure 74: France DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 75: France DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 76: France DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 77: France DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 78: France DALYs of Diabetes Mellitus (2013-2016 %)
Figure 79: APAC Bio CMO Size, By Value, 2013-2017 (USD Billion)
Figure 80: APAC Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Figure 81: South East Asia, East Asia, Oceania , DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 82: South East Asia, East Asia, Oceania DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 83: South East Asia, East Asia, Oceania DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 84: South East Asia, East Asia, Oceania DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 85: South East Asia, East Asia, Oceania DALYs of Diabetes Mellitus (2013-2016 %)
Figure 86: China DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 87: China DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 88: China DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 89: China DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 90: China DALYs of Diabetes Mellitus (2013-2016 %)
Figure 91: China Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Figure 92: China Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 93: China Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 94: India Prevalence of Diabetes Mellitus (Per 1,00,000)2013-2016
Figure 95: India Prevalence of Musculoskeletal Disorders (Per 1,00,000) 2013-2016
Figure 96: India Prevalence of Cardiovascular Disorders (Per 1,00,000) 2013-2016
Figure 97: Total Number of People With Infectious Disorder in India (2012-2016)
Figure 98: India DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 99: India DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 100: India DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 101: India DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 102: India DALYs of Diabetes Mellitus (2013-2016 %)
Figure 103: Japan DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 104: Japan DALYs of Chronic Kidney Disease(2013-2016 %)
Figure 105: Japan DALYs of Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 106: Japan DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 107: Japan DALYs of Diabetes Mellitus(2013-2016 %)
Figure 108: Japan Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Figure 109: Japan Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 110: Japan Prevalence of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 111: US Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 112: US Pharmaceutical Spending 2013-2017 in USD Billion
Figure 113: Revenue of companies engaged in speciality pharmacy in US 2016 (in million USD)
Figure 114: Denmark Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 115: Germany Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 116: Revenue of Germany Pharmaceutical Industry 2012-2016 in Billion USD
Figure 117: Switzerland Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 118: Swiss pharmaceutical industry export 2000
Figure 119: Swiss pharmaceutical industry export 2016
Figure 120: Korea Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 121: Japan Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 122: China Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 123: China Expenditure on Health and Medical Care 2012-2018 (in USD Billion)
Figure 124: Other’s Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 125: Lonza, Net Sales, 2014-2017 (In Billion USD)
Figure 126: Boehringer Ingelheim, Net Sales, 2013-2016 (In Million USD)
Figure 127: Boehringer Ingelheim Sales by Region, 2016
Figure 128: Boehringer Ingelheim Sales by Segment, 2016
Figure 129: Samsung Biologics, Net Sales, 2014-2017 (In Million USD)
Figure 130: Samsung Biologics, Biomedicine manufacturing plants, 2017
Figure 131: Wuxi Biologics, Net Sales, 2013-2016 (In Million USD)
Figure 132: Wuxi Biologics, Sales by Region, 2016
Figure 133: Boehringer Ingelheim Sales by Segment, 2016
Table 1: Japan Biopharmaceutical Market (100 million USD)
